Picture of Biogen logo

BIIB Biogen Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapSuper Stock

Annual cashflow statement for Biogen, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2017
December 31st
2018
December 31st
2019
December 31st
2020
December 31st
2021
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line2,6704,4745,8894,0611,728
Depreciation
Deferred Taxes
Non-Cash Items473189243-2501,997
Unusual Items
Purchased R&D
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital235400199-187-146
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accrued Expenses
Change in Taxes Payable
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Cash from Operating Activities4,5516,1887,0794,2303,640
Capital Expenditures-1,963-886-670-552-295
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items-1,000-1,1601,140-56.8-269
Acquisition of Business
Sale of Business
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities-2,963-2,046471-609-564
Financing Cash Flow Items-454-1167.9-61-116
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities-2,380-4,472-5,860-5,273-2,086
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-753-3491,689-1,583930

Or unlock with your email

Or unlock with your email